Differential Kinetics of Transport of 2′,3′-Dideoxyinosine and Adenosine via Concentrative Na+ Nucleoside Transporter CNT2 Cloned from Rat Blood-Brain Barrier
- Dr. William M. Pardridge, UCLA Warren Hall (13-164), 900 Veteran Ave., Los Angeles, CA 90024. E-mail:wpardridge{at}mednet.ucla.edu
Abstract
The concentrative Na+ nucleoside transporter type 2 (CNT2), cloned from a rat blood-brain barrier cDNA library, yields very high flux ratios for purine nucleosides after expression in frog oocytes. This high activity of the rat CNT2 produced from the blood-brain barrier-derived cDNA, designated clone A-11, enabled a kinetic analysis of 2′,3′-dideoxyinosine transport via the rat CNT2. CNT2 transported both adenosine and 2′,3′-dideoxyinosine. The 2′,3′-dideoxyinosine transport parameters included a Km of 29.2 ± 8.3 μM, a Vmax of 0.40 ± 0.11 pmol/oocyte/min, and a constant of nonsaturable transport (KD) of 15.7 ± 0.6 nl/oocyte/min. The 2′,3′-dideoxyinosine Vmax was 27-fold lower than the adenosine Vmax and the 2′,3′-dideoxyinosine KD was >15-fold greater than the KD of adenosine transport. Adenosine inhibited both the saturable component of 2′,3′-dideoxyinosine transport with a KI of 14.8 ± 1.6 μM, and inhibited the nonsaturable component of 2′,3′-dideoxyinosine transport. Both the saturable and nonsaturable components of 2′,3′-dideoxyinosine transport were sodium-dependent with a sodium K0.5 of 8.7 ± 0.9 mM, and a Hill coefficient of 1.00 ± 0.10. The transport of 2′,3′-dideoxyinosine was strongly inhibited by thymidine, whereas thymidine was a weak inhibitor of adenosine transport via rat CNT2. Thymidine was transported by rat CNT2 with aKm = 130 ± 44 μM and aVmax = 1.7 ± 0.5 pmol/oocyte/min. These studies provide evidence for asymmetric transport sites on rat CNT2, where 2′,3′-dideoxyinosine and thymidine compete selectively at a low Vmax site on the transporter, whereas adenosine is transported at a high Vmaxsite.
Footnotes
-
This study was supported by National Institutes of Health Grant MH-61138.
- Abbreviations:
- AIDS
- acquired immune deficiency syndrome
- DDI
- dideoxyinosine
- BBB
- blood-brain barrier
- AZT
- azidothymidine
- CNT2
- concentrative Na+ nucleoside transporter type 2
- DDA
- dideoxyadenosine
- cRNA
- cloned RNA
- VD
- volume of distribution
- Cl
- clearance
- DDC
- dideoxycytidine
- rCNT2
- rat concentrative Na+ nucleoside transporter type 2
- hCNT2
- human concentrative Na+ nucleoside transporter type 2
-
- Received June 12, 2001.
- Accepted August 6, 2001.
- The American Society for Pharmacology and Experimental Therapeutics



